OrbiMed Buys $20M in Electra IPO, Converts $69M Preferred Stake
ETRA is trading near its 52-week low of $12.5 (0.0% above the low).
Summary
OrbiMed Advisors bought $20M of Electra Therapeutics stock in the IPO and converted its $69M preferred stake into common shares, becoming a major post-IPO holder.
Updates
· SEC SCHEDULE 13D — OrbiMed reports aggregate beneficial ownership of 6,885,170 shares, an 11.0% stake, after IPO conversion and purchases.
Key Events · Ownership and Investor Activity · ETRA
-
OrbiMed Buys $20M in IPO
OrbiMed Advisors purchased 1,333,333 shares at $15.00 per share for $19,999,995 in Electra's IPO on September 21, 2026.
-
Preferred Stock Converts to Common
5,551,837 shares of Series A/B/C Convertible Preferred Stock automatically converted into common stock upon IPO closing, with no additional consideration paid.
-
Post-IPO Ownership
OrbiMed reports beneficial ownership of 5,126,891 shares after the transactions, held through OrbiMed Private Investments VII and OrbiMed Genesis Master Fund.
-
Stock Trades Below IPO Price
Electra shares closed at $12.50 on September 23, 2026, below the $15.00 IPO price, suggesting post-IPO selling pressure despite OrbiMed's endorsement.
Analysis · ETRA · Life Sciences
A leading life-sciences investor and 10% owner, OrbiMed, purchased 1,333,333 shares at the $15.00 IPO price for $19,999,995 and converted 5,551,837 shares of Series A/B/C Preferred Stock into common stock upon the IPO closing. The conversion was automatic and required no additional payment. This is a strong endorsement from a sophisticated healthcare investor, but the stock now trades at $12.50, below the $15.00 IPO price, indicating post-IPO selling pressure.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETRA was trading at $12.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $795.3M. The 52-week trading range was $12.50 to $15.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.